Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 39

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer

Not yet recruiting

Study of tamoxifen loading dose and Ki67 response in breast cancer patients before surgery (ENDO-67)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Prostate cancer

Not yet recruiting

Study of vinorelbine and cisplatin with radiation therapy for patients with castration- and taxane-resistant prostate cancer

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Tartu University Hospital

Infertility male

Not yet recruiting

Study of transdermal testosterone gel to improve ovarian response in women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Instituto Bernabeu S.L.

Germ cell cancer

Not yet recruiting

Study of dornase alfa and cisplatin treatment for patients with refractory germ cell cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Narodny Onkologicky Ustav

Prostate cancer

Not yet recruiting

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Universitaetsklinikum Essen AöR

Breast cancer metastatic

Not yet recruiting

Study of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Curie

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Breast neoplasm

Not yet recruiting

Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Centre Regional Lutte Contre Le Cancer

Endometriosis

Not yet recruiting

Study of cabergoline compared to dienogest and ethinylestradiol for reducing endometriosis symptoms and lesion size in women with confirmed endometriosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cabergoline
  • Sponsor:Hospital Clinico San Carlos

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Amsterdam UMC Stichting

Infertility female

Not yet recruiting

Study of Platelet-Rich Plasma and Growth Factors Given by Ovarian Injection to Women with Low Ovarian Reserve During IVF Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Platelet Concentrate
  • Sponsor:Ivi Alicante S.L.

Prostate cancer

Not yet recruiting

Evaluating Technetium-99m and Cyanine-5 PSMA Tracer-Guided Surgery for Patients with Prostate Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:99MTC-EUK-(SO3)CY5-MAS3
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.